The Incidence of Guillain-Barré Syndrome during COVID-19 Pandemic: A Portuguese Multicentric Retrospective Study
DOI:
https://doi.org/10.46531/sinapse/AO/230055/2023Keywords:
COVID-19/complications, COVID-19 Vaccines, Guillain-Barre Syndrome/ diagnosis, Guillain-Barre Syndrome/ epidemiology, Guillain-Barre Syndrome/ therapy, SARS-CoV-2Abstract
Introduction: Guillain-Barré syndrome (GBS) is a rare peripheral nervous system inflammatory disease with an annual estimated incidence of 1-2/100 000. Several studies relate GBS with vaccination, especially against influenza. The literature is discordant on GBS incidence during the pandemic. Additionally, while vaccination is globally ongoing, GBS cases have been associated with an inoculation against SARS-CoV-2.Objective: To evaluate COVID-19 vaccination-associated Guillain-Barré syndrome cases and to establish their real incidence.
Methods: Multicenter retrospective study with analysis of the GBS incidence and clinical characteristics in the pre-pandemic period (PPP), the pandemic pre-vaccination period (PPVP), and the pandemic vaccination period (PVP).
Results: Forty-seven cases of GBS were identified: 13 in the PPP, 11 in the PPVP and 23 in the PVP. An increase in GBS cases (77%) was observed during the PVP when compared to the PPP, but it was not statistically significant (p = 0.10). Although an increase of the non-AIDP phenotype after vaccination period was observed (34.7%), a statistically significant relationship was not found.
Conclusion: This study is the first Portuguese multicentric study regarding the incidence of GBS and SARS-CoV-2 infection and vaccination. We hypothesize that the slight decrease in GBS during the pandemic pre-vaccination period is probably due to hygienic measures implemented during the COVID-19 pandemic. Moreover, we found a small increase in the number of GBS cases with a possible relationship with COVID-19 vaccination. Prospective studies are necessary to better characterize this relationship and take further conclusions.
Downloads
References
Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Cornblath DR, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15:671-83. doi:10.1038/s41582-019-0250-9
Sheikh BK. Guillain-Barré Syndrome. Continuum. 2020;26:1184-204.
Principi N, Esposito S. Vaccine-preventable diseases, vaccines and Guillain-Barre’ syndrome. Vaccine. 2019;37:5544-50. doi:10.1016/j.vaccine.2018.05.119
Triggle CR, Bansal D, Ding H, Islam MM, Farag EA, Hadi HA, et al. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol. 2021;12:1-23. doi:10.3389/fimmu.2021.631139
Chou SHY, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. Global Incidence of Neurological Manifestations among Patients Hospitalized with COVID-19 - A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. 2021;4:e2112131. doi:10.1001/jamanetworkopen.2021.12131
Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268:1133-70. doi: 10.1007/s00415-020-10124-x.
Sriwastava S, Kataria S, Tandon M, Patel J, Patel R, Jowkar A, et al. Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systemic review of case report and case series. J Neurol Sci. 2021;420:117-263. doi:10.1016/j.jns.2020.117263
Keddie S, Pakpoor J, Mousele C, Patel J, Patel R, Jowkar A, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144:682-93. doi:10.1093/brain/awaa433
Trimboli M, Zoleo P, Arabia G, Gambardella A. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine. Neurol Sci. 2021;42:4401-2. doi: 10.1007/s10072-021-05523-5.
MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:651-6. doi:10.15585/mmwr.mm7017e4
Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus. 2021;13:2-5. doi:10.7759/cureus.13426
Razok A, Shams A, Almeer A, Zahid M. Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. Ann Med Surg. 2021;67:102540. doi:10.1016/j.amsu.2021.102540
McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Rep. 2021;14:e244125. doi:10.1136/bcr-2021-244125
Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep. 2021;14: e243629. doi:10.1136/bcr-2021-243629
Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain–Barré syndrome variant occurring after sars-cov-2 vaccination. Ann Neurol. 2021;90:315-8. doi:10.1002/ana.26144
Maramattom B V., Krishnan P, Paul R, Padmanabhan S, Cherukudal S, Syed AA, et al. Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol. 2021;90:312-4. doi:10.1002/ana.26143
Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, et al. Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine. J Neurol Neurosurg Psychiatry. 2022;93:341-2. doi: 10.1136/jnnp-2021-327027.
Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I, Baleeiro Rodrigues Silva P, Freitas Barboza IC, Vieira Silveira CG, et al. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review. Acta Neurol Scand. 2022;145:393-8. doi: 10.1111/ane.13575.
Finsterer J. SARS-CoV-2 vaccinations are unsafe for those experiencing post-vaccination Guillain-Barre syndrome. Ann Med Surg. 2021;68:102584. doi: 10.1016/j.amsu.2021.102584.
Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27:225-8. doi: 10.1038/s41591-020-1124-9.
Taylor S, Landry CA, Paluszek MM, Groenewoud R, Rachor GS, Asmundson GJ. A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2. Front Psychol. 2020;11:575950. doi:10.3389/fpsyg.2020.575950
Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35:775-9. doi: 10.1007/s10654-020-00671-y.
Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. Eur J Epidemiol. 2020;35:325-30. doi:10.1007/s10654-020-00634-3
Tanislav C, Kostev K. Fewer non-COVID-19 respiratory tract infections and gastrointestinal infections during the COVID-19 pandemic. J Med Virol. 2022;94:298-302. doi:10.1002/jmv.27321.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sinapse
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
